GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vivo Bio Tech Ltd (BOM:511509) » Definitions » EBIT

Vivo Bio Tech (BOM:511509) EBIT : ₹118.4 Mil (TTM As of Mar. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Vivo Bio Tech EBIT?

Vivo Bio Tech's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was ₹29.5 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was ₹118.4 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Vivo Bio Tech's annualized ROC % for the quarter that ended in Mar. 2024 was 4.49%. Vivo Bio Tech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 12.25%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Vivo Bio Tech's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was 8.99%.

Vivo Bio Tech EBIT Historical Data

The historical data trend for Vivo Bio Tech's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vivo Bio Tech EBIT Chart

Vivo Bio Tech Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 70.63 121.50 84.66 122.72 118.38

Vivo Bio Tech Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 48.91 22.00 25.55 41.30 29.53

Competitive Comparison of Vivo Bio Tech's EBIT

For the Biotechnology subindustry, Vivo Bio Tech's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vivo Bio Tech's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vivo Bio Tech's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Vivo Bio Tech's EV-to-EBIT falls into.


Vivo Bio Tech EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹118.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivo Bio Tech  (BOM:511509) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Vivo Bio Tech's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

ROC % (Q: Mar. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2023 ) + Invested Capital (Q: Mar. 2024 ))/ count )
=117.756 * ( 1 - 48.69% )/( (0 + 1346.834)/ 1 )
=60.4206036/1346.834
=4.49 %

where

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=0 - 0 - ( 0 - max(0, 0 - 0+0))
=0

Invested Capital(Q: Mar. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1371.334 - 10.604 - ( 13.896 - max(0, 379.148 - 472.322+13.896))
=1346.834

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Vivo Bio Tech's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2023  Q: Mar. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=118.124/( ( (0 + max(0, 0)) + (814.645 + max(149.888, 0)) )/ 1 )
=118.124/( ( 0 + 964.533 )/ 1 )
=118.124/964.533
=12.25 %

where Working Capital is:

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0 + 0 + 0) - (0 + 0 + 0)
=0

Working Capital(Q: Mar. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(117.95 + 87.74 + 10.579) - (10.604 + 0 + 55.777)
=149.888

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Vivo Bio Tech's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2024 )
=118.385/1316.162
=8.99 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Vivo Bio Tech EBIT Related Terms

Thank you for viewing the detailed overview of Vivo Bio Tech's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Vivo Bio Tech (BOM:511509) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vivo Bio Tech Ltd (BOM:511509) » Definitions » EBIT
Comparable Companies
BOM:526139 BOM:542910 BOM:514336 BOM:539206 BOM:506365 BOM:531207 BOM:524663 BOM:540679 OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX BGNE SZSE:300122
Traded in Other Exchanges
N/A
Address
Number 8-2-672/ 5 and 6, Road Number 1, 3rd Floor, Ilyas Mohammed Khan Estate, Banjara hills, Hyderabad, TG, IND, 500034
Website
http://www.vivobio.com
Vivo Bio Tech Ltd offers drug development and discovery services to pharmaceutical and biotech companies. The company offers services in the areas of In vitro, In vivo, toxicity studies, pharmacological investigations, pharmacokinetic and toxicokinetic studies. It offers services in the areas of pharmacology, toxicology, pathology, analytical chemistry, lab animal diagnostics, custom model generation, custom breeding, surgical models, and molecular biology.

Vivo Bio Tech (BOM:511509) Headlines

No Headlines